Hospital

Phase 3 REST-ON Trial data show that the medication demonstrated clinically meaningful improvement in assessments of disrupted nighttime sleep compared with the placebo.

Those hospitalized for COVID-19 were 21% more likely to develop shingles.

Study finds that health care providers need to reinforce the importance of annual mammograms among patients who survived breast cancer.

In an interview with Pharmacy Times®, Chelsee Jensen, PharmD, pharmaceutical formulary manager at Mayo Clinic, discusses biosimilar usage in health systems and challenges that come with it.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers patients with cancer may experience that oncology pharmacists can help them navigate through.

If all HHC agencies adopted policies requiring staff influenza vaccinations, the researchers predicted an 11.25% reduction in the rate of hospital transfers due to respiratory infections.

Medication reconciliation and pharmacist counseling are crucial to clinical management of patients with hematologic malignancies.

Recent studies that indicated the efficacy of IVIG in patients with myelin oligodendrocyte glycoprotein antibody-associated disease used pediatric cohorts, with few evaluations of the treatment approach in adults.

Study captures the immune effect of the third dose of the COVID-19 vaccine in patients with plasma cell disorders and blood cancers.

Melissa Johnson, MD, program director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses her presentation at the Community Oncology Alliance 2022 conference on new drugs in the non-small cell lung cancer space.

Jim Schwartz, RPh, executive director of pharmacy operations for Oncology Pharmacy Services, discusses his presentation at the Community Oncology Alliance 2022 conference on the new world of oral cancer drug dispensing.

In an interview with Pharmacy Times®, Eric Tichy, PharmD, MBA, BCPS, FAST, FCCP, Vice Chair of Pharmacy/Formulary at Mayo Clinic, discusses some formulary trends in biosimilars at the Academy of Managed Care Pharmacy Annual Meeting.

Additional support is necessary to ensure that infrastructure development continues and that all pharmacists have the necessary tools to continue to provide immunization services.

A recent meta-analysis of statins showed that prevalence of statin intolerance is less than 10%, according to the panel.

Drug meets primary endpoint at 50 mg with reduction in low-density lipoprotein levels from the baseline in the ETESIAN phase 2b trial

Alpelisib is the first FDA-approved treatment for PROS, which is a range of rare conditions characterized by overgrowths and blood vessel anomalies.

Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

Evidence indicates that low-dose tramadol is a generally safe, effective, and fast-acting antidepressant for a substantial number of individuals suffering from depression.

Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.

The value of a patient-first approach and telehealth for addressing the complex health care coordination needs of patients with rare pulmonary diseases has never been more critical than during the COVID-19 pandemic.

The entire pharmacy profession and all those interested in medication safety need to coalesce around the need for systemic change in community pharmacy workplace environments.

Lipitor is an inhibitor of HMG-CoA reductase indicated as an adjunct therapy to diet to treat high cholesterol and triglyceride levels.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.

Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Multiple approaches can be taken to optimize medical therapy in patients with PAD.

Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.